Galectin-3 Inhibits Osteoblast Differentiation through Notch Signaling
Authors:
Open Access
- 1 November 2014
- Vol. 16 (11) , 939-949
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialThe Lancet, 2012
- EGFR signaling suppresses osteoblast differentiation and inhibits expression of master osteoblastic transcription factors Runx2 and osterixJournal of Cellular Biochemistry, 2011
- Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone CellsCancer Cell, 2011
- Bone metastasis: mechanisms and therapeutic opportunitiesNature Reviews Endocrinology, 2011
- Cleavage of galectin‐3 by matrix metalloproteases induces angiogenesis in breast cancerInternational Journal of Cancer, 2010
- Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival SignalsCancer Cell, 2009
- The many facets of Notch ligandsOncogene, 2008
- Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiationNature Medicine, 2008
- Regulation of Tumor Progression by Extracellular Galectin-3Cancer Microenvironment, 2008
- Mutations in NOTCH1 cause aortic valve diseaseNature, 2005